Compare CDNA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | ARQT |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 712.2M | 3.3B |
| IPO Year | 2014 | 2020 |
| Metric | CDNA | ARQT |
|---|---|---|
| Price | $19.73 | $29.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $26.67 | $24.83 |
| AVG Volume (30 Days) | 808.1K | ★ 1.9M |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $357,998,000.00 | $317,929,000.00 |
| Revenue This Year | $14.11 | $85.51 |
| Revenue Next Year | $11.75 | $30.74 |
| P/E Ratio | $16.48 | ★ N/A |
| Revenue Growth | 14.46 | ★ 129.21 |
| 52 Week Low | $10.96 | $11.13 |
| 52 Week High | $25.95 | $31.77 |
| Indicator | CDNA | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 56.62 |
| Support Level | $19.01 | $27.55 |
| Resistance Level | $20.61 | $30.26 |
| Average True Range (ATR) | 0.84 | 1.07 |
| MACD | -0.08 | -0.30 |
| Stochastic Oscillator | 53.52 | 45.09 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.